Talbot Financial LLC Buys 262 Shares of Eli Lilly and Company (NYSE:LLY)

Talbot Financial LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,926 shares of the company’s stock after acquiring an additional 262 shares during the quarter. Eli Lilly and Company accounts for 1.7% of Talbot Financial LLC’s portfolio, making the stock its 21st largest position. Talbot Financial LLC’s holdings in Eli Lilly and Company were worth $12,390,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. CCG Wealth Management LLC bought a new stake in Eli Lilly and Company during the first quarter worth about $257,000. Miracle Mile Advisors LLC raised its holdings in shares of Eli Lilly and Company by 11.7% in the first quarter. Miracle Mile Advisors LLC now owns 5,743 shares of the company’s stock valued at $4,468,000 after buying an additional 600 shares during the last quarter. Little House Capital LLC lifted its position in Eli Lilly and Company by 39.3% during the 1st quarter. Little House Capital LLC now owns 3,503 shares of the company’s stock worth $2,725,000 after buying an additional 988 shares in the last quarter. Kowal Investment Group LLC grew its holdings in Eli Lilly and Company by 18.5% during the 1st quarter. Kowal Investment Group LLC now owns 1,103 shares of the company’s stock worth $858,000 after acquiring an additional 172 shares during the last quarter. Finally, Horizon Wealth Management LLC bought a new stake in Eli Lilly and Company during the 1st quarter worth about $224,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

LLY stock opened at $914.37 on Tuesday. Eli Lilly and Company has a 1-year low of $434.34 and a 1-year high of $916.83. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The firm has a market cap of $869.03 billion, a PE ratio of 134.66, a P/E/G ratio of 1.97 and a beta of 0.41. The business’s 50-day moving average price is $814.40 and its two-hundred day moving average price is $740.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter last year, the firm posted $1.62 earnings per share. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. As a group, research analysts forecast that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders sold 791,145 shares of company stock valued at $673,704,508 over the last quarter. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research reports. Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Truist Financial reiterated a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $812.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.